We are live on ! Find out more
PYXS icon

Pyxis Oncology
PYXS

39 hedge funds and large institutions have $47.7M invested in Pyxis Oncology in 2022 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 8 increasing their positions, 15 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

3.21% more ownership

Funds ownership: 57.83% → 61.04% (+3.2%)

13% less funds holding

Funds holding: 45 → 39 (-6)

31% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 16

37% less capital invested

Capital invested by funds: $76.1M → $47.7M (-$28.4M)

47% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 15

Holders
39
Holders Change
-6
Holders Change %
-13.33%
% of All Funds
0.66%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
8
Reduced
15
Closed
16
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
LCM
Laurion Capital Management
New York
+$5.19M
2
TCM
Tang Capital Management
California
+$3.67M
3
CS
Credit Suisse
Switzerland
+$2.57M
4
NM
Newtyn Management
New York
+$2.13M
5
ACP
Acuta Capital Partners
California
+$1.19M

Top Sellers

1
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$5.49M
2
RI
RTW Investments
New York
-$3.83M
3
RCM
RA Capital Management
Massachusetts
-$3.54M
4
HM
HealthCor Management
New York
-$879K
5
BlackRock
BlackRock
New York
-$840K
Name Holding Trade Value Shares
Change 		Change in
Stake
LCM
1
Laurion Capital Management
New York
$7.55M +$5.19M +1,950,971 +160%
BI
2
BVF Inc
California
$6.99M +$205K +77,000 +3%
PA
3
Perceptive Advisors
New York
$3.64M – – –
Citadel Advisors
4
Citadel Advisors
Florida
$3.62M -$4.16K -1,562 -0.1%
TCM
5
Tang Capital Management
California
$3.28M +$3.67M +1,379,080 New
CS
6
Credit Suisse
Switzerland
$2.3M +$2.57M +965,465 New
RCM
7
RA Capital Management
Massachusetts
$2.27M -$3.54M -1,328,780 -58%
Barclays
8
Barclays
United Kingdom
$2.25M -$4.62K -1,736 -0.2%
Vanguard Group
9
Vanguard Group
Pennsylvania
$2.02M +$859K +322,771 +61%
NM
10
Newtyn Management
New York
$1.9M +$2.13M +800,000 New
HA
11
HHLR Advisors
Cayman Islands
$1.82M – – –
TCM
12
Tekla Capital Management
Massachusetts
$1.69M – – –
RI
13
RTW Investments
New York
$1.62M -$3.83M -1,438,540 -68%
CAM
14
Cormorant Asset Management
Massachusetts
$1.59M – – –
ACP
15
Acuta Capital Partners
California
$1.53M +$1.19M +445,149 +223%
Citigroup
16
Citigroup
New York
$744K +$211K +79,282 +34%
LGM
17
Logos Global Management
California
$525K -$176K -66,218 -23%
BlackRock
18
BlackRock
New York
$489K -$840K -315,597 -61%
Millennium Management
19
Millennium Management
New York
$340K +$380K +142,815 New
Morgan Stanley
20
Morgan Stanley
New York
$325K +$356K +133,691 +4,196%
Geode Capital Management
21
Geode Capital Management
Massachusetts
$261K -$226K -84,730 -44%
Renaissance Technologies
22
Renaissance Technologies
New York
$179K +$201K +75,371 New
BCM
23
Bridgeway Capital Management
Texas
$167K +$187K +70,295 New
Two Sigma Investments
24
Two Sigma Investments
New York
$101K +$113K +42,296 New
E
25
Ergoteles
New York
$87K +$96.9K +36,415 New
1
2 3

PYXS Hedge Fund Activity: Q2 2022 in Review

39 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Pyxis Oncology (PYXS) for Q2 2022, worth a combined $47.7M — down 37% from $76.1M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of PYXS and 11 opened new positions — a net loss of 5 holders — while 15 trimmed existing stakes and 8 added.

The largest buyer was Laurion Capital Management, adding an estimated $5.19M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $5.49M sold.

  • 39 institutional investors held Pyxis Oncology (PYXS) as of Q2 2022, down from 45 in Q1 2022.
  • Funds reported $47.7M of Pyxis Oncology stock for Q2 2022, down 37% quarter-over-quarter.
  • 11 funds opened new Pyxis Oncology positions in Q2 2022 and 16 closed out, a net change of -5 holders.
  • The largest Pyxis Oncology buyer in Q2 2022 was Laurion Capital Management, an estimated $5.19M added.
  • The largest Pyxis Oncology seller in Q2 2022 was Janus Henderson Group, an estimated $5.49M sold.

Based on aggregated 13F filings for Q2 2022.